Sartorius (OTCMKTS:SARTF) Hits New 52-Week High - Here's Why

Key Points

• Sartorius hit a new 52-week high of $226.33 during mid-day trading and was trading up about 0.6%, with the 50-day SMA at $226.33 and the 200-day SMA at $219.72.
• The stock carries a market cap of $7.75 billion and a high valuation with a P/E of 105.27, while its debt-to-equity is 0.89 and liquidity metrics show a current ratio of 0.95 and quick ratio of 0.49.
• Sartorius is a Germany-based provider of laboratory and bioprocessing equipment organized into two divisions—Bioprocess Solutions and Lab Products & Services—serving biopharma, vaccine and advanced therapy makers.

Sartorius (OTCMKTS:SARTF - Get Free Report) hit a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $226.33 and last traded at $226.33, with a volume of 1 shares. The stock had previously closed at $225.00.

Sartorius Trading Up 0.6%

The firm has a fifty day simple moving average of $226.33 and a 200-day simple moving average of $219.72. The firm has a market cap of $7.75 billion, a P/E ratio of 105.27 and a beta of 0.98. The company has a debt-to-equity ratio of 0.89, a current ratio of 0.95 and a quick ratio of 0.49.

Sartorius Company Profile

Sartorius AG, trading in the U.S. over the counter under the symbol SARTF, is a Germany-based provider of laboratory and bioprocessing equipment for the pharmaceutical, biotechnology and research industries. The company is organized into two core divisions: Bioprocess Solutions, which focuses on single-use consumables, filtration technologies and upstream and downstream processing systems; and Lab Products & Services, which supplies laboratory instruments, consumables and services, including balances, pipettes, cell counting systems and water purification units.

The Bioprocess Solutions segment serves customers engaged in the development and manufacture of biopharmaceuticals, vaccines and advanced therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.